A screening tool for therapeutic monoclonal antibodies: Identifying the most stable protein and its best formulation based on thioflavin T binding

Biotechnology Journal

Volumn 7, Issue 1, 2012, Pages 127-132

  Kayser, Veysel ^a   Chennamsetty, Naresh ^a   Voynov, Vladimir ^a   Helk, Bernhard ^b   Forrer, Kurt ^b   Trout, Bernhardt L ^a  

^a USA   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Monoclonal antibody; Protein folding and aggregation; Protein stability; Shelf life estimation; Stability prediction

Indexed keywords

AGGREGATION PROPENSITY; ALTERNATIVE METHODS; FAST SELECTION; MONOCLONAL ANTIBODIES (MAB); PROTEIN STABILITY; SCREENING TOOL; SHELF LIFE; SHORT DURATIONS; STABILITY PREDICTION; THERAPEUTIC MONOCLONAL ANTIBODIES; THERAPEUTIC PROTEIN; THIOFLAVIN T;

AGGREGATES; CHEMICAL DETECTION; MONOCLONAL ANTIBODIES; PROTEIN FOLDING; SIZE EXCLUSION CHROMATOGRAPHY; SURFACE PLASMON RESONANCE;

PROTEINS;

MONOCLONAL ANTIBODY; THIOFLAVINE;

ACCURACY; ARTICLE; BINDING AFFINITY; BINDING KINETICS; BIOLOGICAL ACTIVITY; DRUG FORMULATION; DRUG SCREENING; FLUORESCENCE; GEL PERMEATION CHROMATOGRAPHY; HYDROPHOBICITY; IMMUNE RESPONSE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN STABILITY;

ANTIBODIES, MONOCLONAL; CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY, GEL; FLUORESCENT DYES; PROTEIN FOLDING; PROTEIN STABILITY; PROTEINS; THIAZOLES;

EID: 84855575327     PISSN: 18606768     EISSN: 18607314     Source Type: Journal    
DOI: 10.1002/biot.201100366     Document Type: Article

References (20)

1. Carpenter, J. F., Randolph, T. W., Jiskoot, W., Crommelin, D. J. A. et al., Potential inaccurate quantitation and sizing of protein aggregates by size exclusion chromatography: Essential need to use orthogonal methods to assure the quality of therapeutic protein products. J. Pharm. Sci. 2010, 99, 2200-2208.
2. Bond, M. D., Panek, M. E., Zhang, Z., Wang, D. et al., Evaluation of a dual-wavelength size exclusion HPLC method with improved sensitivity to detect protein aggregates and its use to better characterize degradation pathways of an IgG1 monoclonal antibody. J. Pharm. Sci. 2009, 99, 2582-2597.
3. Semisotnov, G. V., Rodionova, N. A., Razgulyaev, O. I., Uversky, V. N. et al., Study of the "molten globule" intermediate state in protein folding by a hydrophobic fluorescent probe. Biopolymers 1991, 31, 119-128.
4. Kayser, V., Chennamsetty, N., Voynov, V., Helk, B., Trout, B. L., Stability and aggregation of therapeutic monoclonal antibodies studied with ANS and Thioflavin T binding. mAbs 2011, 4, 408-411.
5. Levine, H. I., Thioflavine T interaction with synthetic Alzheimer's disease β-amyloid peptides: Detection of amyloid aggregation in solution. Protein Sci. 1993, 2, 404-410.
6. Stryer, L., The interaction of a naphthalene dye with apomyoglobin and apohemoglobin: A fluorescent probe of non-polar binding sites. J. Mol. Biol. 1965, 13, 482-495.
7. He, F., Hogan, S., Latypov, R. F., Narhi, L. O., Razinkov, V. I., High throughput thermostability screening of monoclonal antibody formulations. J. Pharm. Sci. 2010, 99, 1707-1720.
8. Demeule, B., Lawrence, M. J., Drake, A. F., Gurny, R., Arvinte, T., Characterization of protein aggregation: The case of a therapeutic immunoglobulin. Biochim. Biophys. Acta 2007, 1774, 146-153.
9. Hawe, A., Friess, W., Sutter, M., Jiskoot, W., Online fluorescent dye detection method for the characterization of immunoglobulin G aggregation by size exclusion chromatography and asymmetrical flow field flow fractionation. Anal. Biochem. 2008, 378, 115-122.
10. He, F., Phan, D. H., Hogan, S., Bailey, R. et al., Detection of IgG aggregation by a high throughput method based on extrinsic fluorescence. J. Pharm. Sci. 2010, 99, 2598-2608.
11. Kayser, V., Chennamsetty, N., Voynov, V., Helk, B. et al., Evaluation of a non-Arrhenius model for therapeutic monoclonal antibody aggregation. J. Pharm. Sci. 2011, 100, 2526-2542.
12. Black, S. D., Mould, D. R., Development of hydrophobicity parameters to analyze proteins which bear post- or cotranslational modifications. Anal. Biochem. 1991, 193, 72-82.
13. Krebs, M. R. H., Bromley, E. H. C., Donald, A. M., The binding of thioflavin-T to amyloid fibrils: localisation and implications. J. Struct. Biol. 2005, 149, 30-37.
14. LeVine, H., Ronald, W., Quantification of β-sheet amyloid fibril structures with thioflavin T. Methods Enzymol. 1999, 309, 274-284.
15. Biancalana, M., Makabe, K., Koide, A., Koide, S., Molecular mechanism of thioflavin-T binding to the surface of β-rich peptide self-assemblies. J. Mol. Biol. 2009, 385, 1052-1063.
16. Groenning, M., Norrman, M., Flink, J. M., van de Weert, M. et al., Binding mode of thioflavin T in insulin amyloid fibrils. J. Struct. Biol. 2007, 159, 483-497.
17. Chennamsetty, N., Voynov, V., Kayser, V., Helk, B., Trout, B. L., Prediction of aggregation prone regions of therapeutic proteins. J. Phys. Chem. B 2010, 114, 6614-6624.
18. Lacy, E. R., Baker, M., Brigham-Burke, M., Free sulfhydryl measurement as an indicator of antibody stability. Anal. Biochem. 2008, 382, 66-68.
19. McAuley, A., Jacob, J., Kolvenbach, C. G., Westland, K. et al., Contributions of a disulfide bond to the structure, stability, and dimerization of human IgG1 antibody CH3 domain. Protein Sci. 2008, 17, 95-106.
20. Chennamsetty, N., Helk, B., Voynov, V., Kayser, V., Trout, B. L., Aggregation-prone motifs in human immunoglobulin G. J. Mol. Biol. 2009, 391, 404-413.